ReviewJournal of neuro-oncology2009
Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas.
Review in Journal of neuro-oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 71 citations in OpenAlex.
- Case Report: [Frontiers in oncology · 2026Article
- Benign tumors broaden the field of application for immunotherapy.Frontiers in immunology · 2025Review
- Case Report: Advanced grade 2 meningioma withFrontiers in oncology · 2025Article
- The Impact of Molecular and Genetic Analysis on the Treatment of Patients with Atypical Meningiomas.Diagnostics (Basel, Switzerland) · 2024Review
- Minimally Invasive Approaches in the Surgical Treatment of Intracranial Meningiomas: An Analysis of 54 Cases.Brain tumor research and treatment · 2024Article
- Domestic Animal Models of Central Nervous System Tumors: Focus on Meningiomas.Life (Basel, Switzerland) · 2023Review
- Review
- Article
- Spinal Meningiomas.Advances in experimental medicine and biology · 2023Article
- Gemcitabine in Recurrent Meningioma.South Asian journal of cancer · 2020Article
- Molecular characteristics of meningiomas.Journal of pathology and translational medicine · 2020Review
- Emerging Medical Treatments for Meningioma in the Molecular Era.Biomedicines · 2018Review
- Predictors of Treatment Response and Survival Outcomes in Meningioma Recurrence with Atypical or Anaplastic Histology.Neurosurgery · 2018Article
- The current status of 5-ALA fluorescence-guided resection of intracranial meningiomas-a critical review.Neurosurgical review · 2015Review
- Assessment of the treatment response of spinal meningiomas after radiosurgery focusing on serial MRI findings.Japanese journal of radiology · 2015Article
- Expression of astrocyte elevated gene-1 (AEG-1) in human meningiomas and its roles in cell proliferation and survival.Journal of neuro-oncology · 2015Article
- Cucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis.BMC complementary and alternative medicine · 2013Article
- IFN-α for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series.CNS oncology · 2013Article
- Is there effective systemic therapy for recurrent surgery- and radiation-refractory meningioma?CNS oncology · 2013Article
- Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.Journal of neuro-oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningioma is a common intracranial tumor, originating from the meninges of the skull or spinal canal. Most meningiomas are benign tumors, however atypical or anaplastic tumors can be found in 6% of cases. Patients with asymptomatic small benign meningiomas can be followed without therapy, but in symptomatic patients complete surgical resection should be performed. For recurrent previously resected tumors re-resection is recommended followed by radiotherapy in selected cases. Antiprogesterone treatment can also be considered in recurrent benign meningiomas. Immunotherapy with interferon-alpha and chemotherapy should be reserved for all cases of recurrent meningiomas (benign, atypical, and malignant) when all the standard therapies have failed or contraindicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.